NanoViricides Signs Comprehensive Antiviral Drug Agreement With TheraCour Pharma

SHELTON, CT / ACCESSWIRE / September 26, 2024 / NanoViricides, Inc. (NYSE American: NNVC), a leading clinical-stage developer of broad-spectrum antiviral nanomedicines, has secured a right of first refusal (ROFR) for all antiviral drug developments from TheraCour Pharma, Inc. This agreement, signed on September 23, 2024, grants NanoViricides key intellectual property rights for developing treatments against numerous viral infections.

The company's lead drug, NV-387, has shown significant effectiveness against various viruses in animal studies. The MoU permits rapid discovery and addition of new antiviral indications for NV-387 to NanoViricides' development pipeline.

Additionally, the company has developed "Trojan Horse" drugs designed to cure most viral infections by attacking the virus in multiple ways. The MoU expands NanoViricides' ability to rapidly develop such drugs for public health threats, including unpredictable and emergent viruses.

This new agreement enhances NanoViricides' capabilities to develop multiple drug candidates for various antiviral applications, streamlining the process for licensing specific antiviral fields between the two parties.